ADRB2-Targeting Therapies for Prostate Cancer

ADRB2-Targeting Therapies for Prostate Cancer

There is accumulating evidence that β-2 adrenergic receptor (ADRB2) signaling contributes to the progression and therapy resistance of prostate cancer, whereas availability of clinically tested β-blocker propranolol makes this pathway especially attractive as potential therapeutic...

Full description

Bibliographic Details
Main Author: George Kulik
Format: Article
Language:English
Published: MDPI AG 2019-03-01
Series:Cancers
Subjects:
β-2 adrenergic receptor (ADRB2)
cAMP-dependent protein kinase (PKA)
prostate cancer
propranolol
apoptosis
clinical trial
BCL-2-associated death promoter (BAD)
myeloid cell leukemia 1 (MCL-1)
Online Access:http://www.mdpi.com/2072-6694/11/3/358

Internet

http://www.mdpi.com/2072-6694/11/3/358

Similar Items